Fate of 35S-Cystine in Multiple Myeloma
Author Information
Author(s): E. Siegel, B. A. Sachs, F. A. Graig
Primary Institution: Montefiore Hospital
Hypothesis
What is the fate of 35S labelled cystine in patients with multiple myeloma compared to other malignant neoplasms?
Conclusion
The study found that the turnover and excretion of 35S administered as cystine are much slower in multiple myeloma patients compared to those with other neoplasms.
Supporting Evidence
- The 35S blood levels declined slowly, remaining about three-quarters of the initial values after five days.
- The average zero-time space of dilution was 7.39 liters for myeloma patients.
- Urinary excretion of 35S was low, with only 13.6 to 30.9 percent of the dose appearing in urine within 72 hours.
- Patients with multiple myeloma had longer initial and late half-disappearance times compared to those with other neoplasms.
Takeaway
Doctors gave a special type of cystine to patients with blood cancer and found it stayed in their bodies longer than in other patients.
Methodology
Intravenous administration of 35S-labeled cystine to 5 patients with multiple myeloma and 5 with other neoplastic diseases, followed by blood and urine analysis over 14 days.
Limitations
The study did not involve the analysis of individual globulins, which may have shown greater differences in turnover rates.
Participant Demographics
Five patients with multiple myeloma and five with other neoplastic diseases.
Want to read the original?
Access the complete publication on the publisher's website